Avara Pharmaceutical sign agreement to acquire Reims from AstraZeneca in France

Avara Pharmaceutical Services has signed and closed on an agreement with AstraZeneca to acquire the Reims, France manufacturing and distribution facility. “This key acquisition is another important component of our strategic plan that further expands our services,” stated Timothy C. Tyson, Chairman and CEO.

Avara Pharmaceutical Services is a state-of-the-art contract manufacturing and technical services organization providing both API formulation and manufacturing, along with secondary formulation, manufacturing, packaging and distribution of small molecule drugs, including highly potent compounds. Avara has secondary manufacturing technologies including granulation, coating, blending, encapsulation, compression and drying of tablets and capsules. Avara also has secondary sterile manufacturing capability in the Liscate site.

Welcoming the Reims team to Avara Pharmaceutical Services, the company now has eight sites: three in the US, including the corporate HQ’s; one in Puerto Rico; one in the UK; one in Ireland; one in Italy and this new additional site in France.

1. Norwalk, CT (USA) – Corporate HQ 2. Arecibo, Puerto Rico -Development, Secondary manufacturing and packaging 3. Shannon, Ireland – Development and API formulation and manufacturing 4. Norman, OK (USA) -Development and Secondary manufacturing and packaging 5. Avlon, United Kingdom –Development and API formulation and manufacturing 6. Liscate, Italy-Development and Sterile Manufacturing 7. Aiken, South Carolina–Secondary manufacturing and packaging 8. Reims, France – Development and Secondary manufacturing, packaging and distribution

“With rapid expansion and integration set for 2017-2018, we continue, with great confidence, to build a pharmaceutical services company with complementary offerings in key regions to serve the rapidly growing market. Each site has significant professional experience, state of the art capability and a long history of delivering high quality pharmaceuticals that meet or exceed customer expectations and regulatory requirements in every major market around the world. The people who are a part of the Avara team are the key to our long-term success,” said Tyson.

Image: Tim Tyson, a global leader in the pharmaceutical industry, is Chairman and CEO of Avara Pharmaceutical Services. In his 35-plus year career, Mr. Tyson has negotiated complex multi-billion dollar mergers and acquisitions, led major turn-arounds that have fueled growth and value and, most significantly, has been instrumental in bringing more than 50 lifesaving and life improving medicines to the market. (Source: Avara Pharma)